Gilead Sciences reported that selonsertib (also known as GS-4997), an investigational treatment for pulmonary arterial hypertension (PAH), did not achieve the primary endpoint in an analysis of ARROW, a Phase 2 clinical trial (NCT02234141) evaluating the drug’s efficacy, safety and tolerability. The company also reported top-line data from two other…
News
A team of researchers at Columbia University Medical Center and New York Presbyterian Hospital advise patients with pulmonary hypertension no to become pregnant, based on the case of a 28-year-old woman who was diagnosed with chronic thromboembolic pulmonary hypertension (CTEPH), or group 4 pulmonary hypertension, during her pregnancy.
Pregnancy can be a trigger for pulmonary arterial hypertension (PAH) in women with a genetic predisposition to the disease, according to a case study published in the journal Pulmonary Circulation. In the study, “Pregnancy As A Possible Trigger For Heritable Pulmonary Arterial Hypertension,” researchers detail the development of aggressive PAH during…
For the first time, people affected by a host of different diseases, mainly conditions affecting the heart, lungs, kidneys, and liver, met with members of the European parliament to brainstorm ways to efficiently solve issues regarding organ donation and transplant. Healthcare experts, patients, and their families were at the Oct. 18 meeting,…
Bayer will present new data from two different studies of Adempas (riociguat) for pulmonary arterial hypertension (PAH) at the American College of Chest Physicians (CHEST) 2016 Annual Meeting Oct. 22-26 in Los Angeles. One of the presentations will be held during the Late-Breaking Abstracts session of the meeting. Bayer will also…
The Pulmonary Hypertension Association (PHA) is planning a series of events for November, Pulmonary Hypertension Awareness Month, including a daylong focus on chronic thromboembolic pulmonary hypertension (CTEPH), a form of pulmonary hypertension (PH) that results from blood clots in the lungs. Events planned for CTEPH Awareness Day, Nov. 15, include promoting information about the two…
Patients with pulmonary arterial hypertension (PAH) have higher than usual blood levels of S1P, a molecule that promotes worsening disease, according to a study published in the journal Pulmonary Circulation. The researchers, working in a rat PAH model, also found that blocking this protein improved pulmonary arterial structure and cardiac function, suggesting…
Tyvaso (treprostinil sodium), a drug approved for enhancing exercise capacity in patients with pulmonary arterial hypertension (PAH), was reported in a recent study to be well tolerated and safe in routine clinical use. The study, “An observational study of inhaled-treprostinil respiratory-related safety in patients with pulmonary arterial hypertension,” was published…
A specific gene known as CYP2C44, more active in women with pulmonary hypertension (PH) than in men, may be a key factor in protecting them from more severe forms of the disease, according to results of a study performed with animal models. More women are diagnosed with pulmonary arterial hypertension…
Elsevier announced that it is expanding its work with the American College of Chest Physicians (CHEST) to provide CHEST members with detailed and interactive eLearning programs that address their specialities, including pulmonary arterial hypertension (PAH) and chronic obstructive pulmonary disease (COPD). Elsevier is a provider of scientific, technical and medical information products, and the…
Early treatment with Tracleer (bosentan) may delay the development of pulmonary arterial hypertension (PAH) in people with scleroderma, according to a study that compared patients who had never used this medicine with those taking it for digital ulcers. If confirmed in other studies, the finding has the potential to radically change the prognosis for numerous…
Reata Pharmaceuticals has enrolled the first patient in its Phase 3 CATALYST trial (NCT02657356), exploring the potential benefits of bardoxolone methyl in people with pulmonary arterial hypertension (PAH) linked to connective tissue disease. The trial is continuing to recruit participants. The company also reported that data from the ongoing Phase 2 LARIAT…
